Within Asia Pacific, China has the potential to realize the most, from the benefits of precision medicine. Due to its large population, the really well established hospital infrastructure, a large number of biopharmas, as well as diagnostic companies. Collectively, these support the infrastructure we're thinking about for physician medicine and the therapies getting to patients. China has also started one of the first industrial policies. Back then in twenty fifteen, This was called personalized medicine.
Based on the UK estimates, if fully realized over a ten year period, the precision medicines that we're looking at today and tomorrow have the potential of serving ten point five million patients. Now the number might seem small because of the large population, but we need to recognize that we are talking about precision medicine. So that means that they're very targeted towards a particular audience. In addition, this will bring in probably about two hundred billion dollars of investment, and that is across research, development, manufacturing, as well as the clinical skills upgrading throughout China and have the potential of saving the health care thirty billion dollars of cost. And China pledged and eventually achieved, fifteen billion dollars of investment into precision medicine. Even with the investment today and the significant advances in therapies, just imagine why we think that this is not yet fully realized.
First of all, the diagnostics. The diagnostic framework for regulatory approval is complex, and then the reimbursements as well. So you have to go or manufacturer has to go from province to province to seek reimbursement. This generally means that patients do not have access to the diagnostics because it is not reimbursed as quickly as they can.
And then the treatments that's paired with this diagnostics then often are delayed because of that. And collectively, the reimbursements may not be quite sufficient to really cover the cost of the therapy. Given these are generally newer therapies, and more innovative, and also perhaps the entire processes are not fully optimized, given the smaller patient base, The cost can be higher than your typical drugs that's on the market today. Given that these can be a cure, which means that once the therapy is given, the patient may not need any additional support, from the healthcare system or or not support, from the healthcare system or or not significant ones for the rest of their lives.
Our annual based, reimbursement amounts doesn't seem to quite suit. So as of today, there is not a good mechanism to really address these life saving cures over the course of address these life saving cures over the course of time. And this is an area that we like to bring to everyone's attention.
